3685-28-7

Upstream product

• 94-09-7 p-aminoethylbenzoate 
• 64-17-5 ethanol 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 

Downstream Products

• 78431-91-1 4-[Bis-(2-hydroxy-ethyl)-amino]-cyclohexanecarboxylic acid ethyl ester 
• 117130-96-8 C₁₁H₂₂ClN₂O₃P 
• 1357918-57-0 (1s,4s)-ethyl 4-((E)-2-(benzoylimino)-6-(piperidin-1-ylmethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)cyclohexanecarboxylate 
• 1357918-51-4 C₂₄H₂₇N₃O₄ 
• 509093-85-0 ethyl (1s,4s)-4-((4-fluoro-2-nitrophenyl)amino)cyclohexane-1-carboxylate 
• 117112-31-9 ethyl N-phosphoryl-cis-4-aminocyclohexanecarboxylate 
• 117112-28-4 ethyl N-phosphoryl-cis-4-aminocyclohexanecarboxylate 
• 117112-25-1 ethyl N-(N'N'-dimethylamido-N''-morpholido)phosphoryl-cis-4-aminocyclohexanecarboxylate 
• 117112-26-2 ethyl N-(N'N'-dimethylamido-N''-morpholido)phosphoryl-trans-4-aminocyclohexanecarboxylate 
• 78431-94-4 4-[Bis-(2-chloro-ethyl)-amino]-cyclohexanecarboxylic acid ethyl ester; hydrochloride 
• 78431-97-7 4-[Bis-(2-chloro-ethyl)-amino]-cyclohexanecarboxylic acid; hydrochloride 
• 117112-34-2 ethyl N-(N'N'-dimethylamido-N''-cyclohexylamido)-phosphoryl-cis-4-aminocyclohexanecarboxylate 
• 117112-21-7 C₁₃H₂₄Cl₃N₂O₃P 
• 33059-86-8 N--N'-<2-chlor-aethyl>-harnstoff 

Relevant academic research and scientific papers

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer

A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK). Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity. Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors. Compound 49 achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd. Compounds 36 and 49 show favorable potency and PK characteristics in preclinical species indicative of suitability for further development.

METHOD FOR PRODUCING ALKYL TRANS-4-AMINOCYCLOHEXANECARBOXYLATE HYDROCHLORIDE

PROBLEM TO BE SOLVED: To provide a method for industrially advantageously producing a high-purity alkyl trans-4-aminocyclohexanecarboxylate hydrochloride. SOLUTION: Alkyl 4-aminocyclohexanecarboxylates in (50/50) to (0/100) cis/trans isomer ratio are reacted with an amine hydrochloride in a 1-10C aliphatic alcohol and crystallization is then carried out. Thereby, the alkyl trans-4-aminocyclohexanecarboxylate hydrochloride is produced.

Synthesis of analogues of N (2 chloroethyl) N' trans 4 methylcyclohexyl) N nitrosourea for evaluation as anticancer agents

The superior activity of N (2 chloroethyl) N' (trans 4 methylcyclohexyl) N nitrosourea (MeCCNU) against advanced murine Lewis lung carcinoma in comparisons with the cis form and other nitrosoureas prompted the synthesis of a number of MeCCNU analogues, including several cis trans pairs. The methyl group was replaced by a variety of substituents (CO2H, CH2CO2H, CO2Me, CH2OAc, CH2Cl, OMe); the trans 3 methylcyclohexyl, cis 2 methyl 1,3 dithian 5 yl, cis and trans 2 methyl 1,3 dithian 5 yl tetraoxide, and 1 methylhexyl (open chain) analogues were also prepared. Preliminary tests against murine leukemia L1210 revealed therapeutic indices (ED50/LD10) ranging from 0.26 to 0.79; all but 3 analogues effected 50% cure rates at nontoxic doses, the open chain analogue being one of the least active. In terms of therapeutic index, diequatorial (trans 4) isomers were, with one exception, as active as or, in 4 of the 8 examples, somewhat more active than the corresponding axial equatorial (cis 4) isomers. In this series, 4 of the 5 2-fluoroethyl analogues prepared were clearly inferior to the corresponding 2 chloroethyl analogues.